Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
PHASE1CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
February 15, 2019
Primary Completion Date
May 15, 2019
Study Completion Date
June 7, 2019
Conditions
Healthy Males
Interventions
DRUG
Firibastat
Firibastat (QGC001) 500 mg
Trial Locations (1)
Unknown
Quotient Sciences, Nottingham
All Listed Sponsors
collaborator
Quotient Sciences
INDUSTRY
lead
Quantum Genomics SA
INDUSTRY
NCT03714685 - Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations | Biotech Hunter | Biotech Hunter